Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Klebsiella pneumoniae Infections - Overview
Klebsiella pneumoniae Infections - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Klebsiella pneumoniae Infections - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Klebsiella pneumoniae Infections - Companies Involved in Therapeutics Development
Klebsiella pneumoniae Infections - Drug Profiles
Klebsiella pneumoniae Infections - Dormant Projects
Klebsiella pneumoniae Infections - Discontinued Products
Klebsiella pneumoniae Infections - Product Development Milestones
Featured News & Press Releases
Jul 07, 2020: Data published in Ebiomedicine validates novel scientific approach that disarms bacterial defenses to treat or prevent life-threatening infections
Sep 05, 2019: Summit presented in vivo proof of concept data for targeted Enterobacteriaceae antibiotics at ASM/ESCMID Conference
Aug 27, 2019: Vaccine against deadly superbug Klebsiella effective in mice
Aug 20, 2019: Vaxxilon receives grant to develop new prophylactic vaccine
Jul 02, 2019: Appili Therapeutics signs $3M USD grant contract with the United States Department of Defense to develop antibiotics that target superbugs
Apr 03, 2019: Summit’s pipeline expands with series of new mechanism antibiotics targeting Enterobacteriaceae
May 07, 2018: Melinta Therapeutics Receives Up to $6.2 Million from CARB-X to Advance Clinical Development of a Novel Antimicrobial to Combat Antibiotic-Resistant Bacteria
Apr 17, 2018: Arsanis to Present Abstract On ASN300 At The 28th European Congress of Clinical Microbiology And Infectious Diseases
Nov 07, 2017: Appili Therapeutics Receives $1.2M USD from the Department of Defense to Advance Antibiotic Targeting Drug-Resistant Bacteria
Sep 30, 2017: Development of a negamycin alogue targeting the translatiol machinery in gram-negative drug-resistant pathogens for the treatment of Infections
Apr 20, 2017: Arsanis Presents Data on ASN-300 at the 27th European Congress of Clinical Microbiology and Infectious Diseases
Apr 11, 2017: Appili Therapeutics Receives Funding from the Government of Cada to Support Development of New Antibiotic To Treat Gram-Negative Infections
Jun 17, 2016: Arsanis Presents Data at ASM Microbe 2016 Demonstrating Protection Against Klebsiella pneumoniae using Monoclol Antibody Technology
Mar 09, 2015: Phico Therapeutics Receives Translation Award to Advance its SASPject PT4 Aimed at Escherichia coli and Klebsiella pneumoniae Towards Clinical Trials
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development for Klebsiella pneumoniae Infections, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Top 10 Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022

List of Tables

List of Tables
Number of Products under Development for Klebsiella pneumoniae Infections, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Companies, 2022 (Contd..1)
Number of Products under Development by Companies, 2022 (Contd..2)
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Companies, 2022 (Contd..2)
Products under Development by Companies, 2022 (Contd..3)
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Klebsiella pneumoniae Infections - Pipeline by ABAC Therapeutics SA, 2022
Klebsiella pneumoniae Infections - Pipeline by AEON Medix Inc, 2022
Klebsiella pneumoniae Infections - Pipeline by Affinivax Inc, 2022
Klebsiella pneumoniae Infections - Pipeline by Akthelia Pharmaceuticals Ltd, 2022
Klebsiella pneumoniae Infections - Pipeline by Alterity Therapeutics Ltd, 2022
Klebsiella pneumoniae Infections - Pipeline by Appili Therapeutics Inc, 2022
Klebsiella pneumoniae Infections - Pipeline by Armata Pharmaceuticals Inc, 2022
Klebsiella pneumoniae Infections - Pipeline by BB200 LLC, 2022
Klebsiella pneumoniae Infections - Pipeline by Bioversys AG, 2022
Klebsiella pneumoniae Infections - Pipeline by Bugworks Research India Pvt Ltd, 2022
Klebsiella pneumoniae Infections - Pipeline by Celdara Medical LLC, 2022
Klebsiella pneumoniae Infections - Pipeline by CHO Pharma Inc, 2022
Klebsiella pneumoniae Infections - Pipeline by Clarametyx Biosciences Inc, 2022
Klebsiella pneumoniae Infections - Pipeline by ContraFect Corp, 2022
Klebsiella pneumoniae Infections - Pipeline by Dong-A ST Co Ltd, 2022
Klebsiella pneumoniae Infections - Pipeline by Entasis Therapeutics Holdings Inc, 2022
Klebsiella pneumoniae Infections - Pipeline by F. Hoffmann-La Roche Ltd, 2022
Klebsiella pneumoniae Infections - Pipeline by Fedora Pharmaceuticals Inc, 2022
Klebsiella pneumoniae Infections - Pipeline by Forge Therapeutics Inc, 2022
Klebsiella pneumoniae Infections - Pipeline by GSK plc, 2022
Klebsiella pneumoniae Infections - Pipeline by Idorsia Pharmaceutical Ltd, 2022
Klebsiella pneumoniae Infections - Pipeline by Infextious Therapeutic, 2022
Klebsiella pneumoniae Infections - Pipeline by LimmaTech Biologics AG, 2022
Klebsiella pneumoniae Infections - Pipeline by Linnaeus Bioscience Inc, 2022
Klebsiella pneumoniae Infections - Pipeline by Melinta Therapeutics Inc, 2022
Klebsiella pneumoniae Infections - Pipeline by Microbiotix Inc, 2022
Klebsiella pneumoniae Infections - Pipeline by Mikrobiomik Healthcare Company SL, 2022
Klebsiella pneumoniae Infections - Pipeline by Nektr Technologies Ltd, 2022
Klebsiella pneumoniae Infections - Pipeline by Neoculi Pty Ltd, 2022
Klebsiella pneumoniae Infections - Pipeline by Nosopharm SAS, 2022
Klebsiella pneumoniae Infections - Pipeline by Novabiotics Ltd, 2022
Klebsiella pneumoniae Infections - Pipeline by Oryn Therapeutics, 2022
Klebsiella pneumoniae Infections - Pipeline by Pedanius Therapeutics Ltd, 2022
Klebsiella pneumoniae Infections - Pipeline by Peptilogics Inc, 2022
Klebsiella pneumoniae Infections - Pipeline by Phico Therapeutics Ltd, 2022
Klebsiella pneumoniae Infections - Pipeline by Planet Biotechnology Inc, 2022
Klebsiella pneumoniae Infections - Pipeline by Recce Pharmaceuticals Ltd, 2022
Klebsiella pneumoniae Infections - Pipeline by RemAb Therapeutics SL, 2022
Klebsiella pneumoniae Infections - Pipeline by Seres Therapeutics Inc, 2022
Klebsiella pneumoniae Infections - Pipeline by Shionogi & Co Ltd, 2022
Klebsiella pneumoniae Infections - Pipeline by Soligenix Inc, 2022
Klebsiella pneumoniae Infections - Pipeline by Spero Therapeutics Inc, 2022
Klebsiella pneumoniae Infections - Pipeline by Spexis AG, 2022
Klebsiella pneumoniae Infections - Pipeline by Summit Therapeutics Inc, 2022
Klebsiella pneumoniae Infections - Pipeline by Syntiron LLC, 2022
Klebsiella pneumoniae Infections - Pipeline by Taisho Pharmaceutical Holdings Co Ltd, 2022
Klebsiella pneumoniae Infections - Pipeline by Techulon Inc, 2022
Klebsiella pneumoniae Infections - Pipeline by VaxNewMO LLC, 2022
Klebsiella pneumoniae Infections - Pipeline by Venus Medicine Research Centre, 2022
Klebsiella pneumoniae Infections - Dormant Projects, 2022
Klebsiella pneumoniae Infections - Dormant Projects, 2022 (Contd..1)
Klebsiella pneumoniae Infections - Dormant Projects, 2022 (Contd..2)
Klebsiella pneumoniae Infections - Discontinued Products, 2022